Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
351 articles about Travere Therapeutics
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 13, 2024
3/13/2024
Travere Therapeutics, Inc. announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,600 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,600 shares of its common stock.
-
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
3/11/2024
Travere Therapeutics, Inc. announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for conversion of the existing U.S. accelerated approval of FILSPARI® in IgA nephropathy to full approval.
-
Travere Therapeutics to Present at Upcoming March 2024 Investor Conferences
2/26/2024
Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming investor conferences in March.
-
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
2/23/2024
CSL Vifor and Travere Therapeutics, Inc., announced that the European Medicines Agency's CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day. IgAN is a rare kidney disorder and a leading cause of kidney failure.
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
2/15/2024
Travere Therapeutics, Inc. reported its fourth quarter and full year 2023 financial results and provided a corporate update.
-
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
2/8/2024
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close of the U.S. financial markets.
-
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
2/1/2024
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. ET.
-
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
1/25/2024
Travere Therapeutics, Inc., announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.
-
Travere Therapeutics Provides Corporate Update and 2024 Outlook
1/8/2024
Travere Therapeutics, Inc. announced that, based on preliminary and unaudited financial data, the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million.
-
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 p.m. PT.
-
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
12/14/2023
Travere Therapeutics, Inc. announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria.
-
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
12/4/2023
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of a successful pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) in IgA nephropathy (IgAN).
-
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/21/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.
-
Travere Therapeutics Reports Third Quarter 2023 Financial Results
11/7/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2023 financial results and provided a corporate update.
-
Following two late-stage failures, Travere Therapeutics has unveiled the results of two Phase III studies, attempting to regain Filspari’s footing in IgA nephropathy and focal segmental glomerulosclerosis.
-
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
11/3/2023
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
-
Travere Therapeutics to Report Third Quarter 2023 Financial Results
10/24/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the U.S. financial markets.
-
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
10/13/2023
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 2-5, 2023.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 11, 2023
10/11/2023
Travere Therapeutics, Inc. announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 29,250 shares of its common stock.
-
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
9/26/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023.